Immucell reports Q3 revenue $6M, one estimate $5.4M

ImmuCell announced preliminary, unaudited sales results for the third quarter of 2024, which ended September 30. During the three-,nine- and twelve-month periods ended September 30 annualized production output was approximately 73%, 81% and 77%, respectively, of the company’s estimated full capacity of approximately $30M per year. As of September 30 the backlog of orders aggregated approximately $7.3M. The Company believes that the current backlog reflects strong demand as distributors work to replenish their buffer stocks and as end-users place orders in advance of the first quarter calving season…”We continue to work to achieve FDA approval to commercialize Re-Tain ,” commented Michael F. Brigham, President and CEO of ImmuCell. “We plan to provide an update when we have filed our Non-Administrative NADA . We anticipate making this submission later this year, shortly after the inspectional observations at our contract manufacturer are resolved to the satisfaction of the FDA. We have been in discussions with the FDA about an expedited review at that point.”